Lv31
310 积分 2023-12-02 加入
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
3小时前
已完结
Influence of vedolizumab on extraintestinal manifestations in inflammatory bowel disease: a nationwide multicenter study of the GETECCU ENEIDA Registry
17天前
已关闭
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials
2个月前
已完结
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study
3个月前
已完结
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA
5个月前
已完结
The Real-World Impact of Vitamin D Supplementation on Inflammatory Bowel Disease Clinical Outcomes
7个月前
已完结
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial
8个月前
已完结
Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan
9个月前
已完结
皖公网安备34019202002308
